App to support MS patients launched in the UK

Biogen has launched a new app in the UK, Cleo, to provide information and support for people living with multiple sclerosis (MS).

The app can also be used by a patient’s carers, friends and family. The main features of the app include:

  • Information, articles and stories for people living with MS
  • Personal Journal – for patients to keep track of their health and set treatment and appointment reminders
  • Health and wellbeing programmes designed to help patients
  • Cleo Chat – users can chat with a Cleo Advisor who can help them make the most of Cleo articles, programmes and features

Terry O’Regan, vice president and managing director, Biogen UK & Ireland, said: “Biogen believes that, regardless of treatment choices, patients should always be informed, supported and inspired to aim for better tomorrows. Cleo reinforces our ongoing commitment to MS and is an example of our ambition to provide digital solutions that benefit people living with neurological conditions.”

The app was developed by Biogen’s Global digital entity Biogen Healthcare Solutions (BHS) who aim to provide digital solutions that improve patient care. Cleo is already available in Germany, France, Italy, Canada, Japan and the US. Further country launches are scheduled throughout 2019.

Matt Norcross, affiliate head of multichannel excellence (UK) at Biogen, said: “The MS journey is a complex one, and knowing where to go to find trusted information on health and wellbeing can be a key challenge for patients in the UK. Cleo was designed as a simple, personalised mobile solution to support the MS community in keeping track of their health, supporting their wellbeing and learning about the MS topics that matter most to them.”

'App to support MS patients launched in the UK' has no comments

Be the first to comment this post!

Would you like to share your thoughts?

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

© 2019 Rapid Life Sciences Ltd, a Rapid News Group Company. All Rights Reserved.

Privacy policy

Terms and conditions